Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15310330 | 0.99 | CCR1 (0.41) | CCR1CCR8HTR2CMETAP2MEN1 | |
| SCHEMBL13257210 | 0.87 | CCR1 (0.43) | CCR1CCR8METAP2TGFBR1 | |
| Hydrochloric Acid SCHEMBL3708218 | 0.86 | CCR1 (0.42) | CCR1CCR8METAP2TGFBR1 | |
| SCHEMBL13257284 | 0.83 | KMT2A (0.44) | MEN1KMT2AUSP7POLBSLC18A3 | |
| Hydrochloric Acid SCHEMBL3705119 | 0.82 | KMT2A (0.43) | HTR2CMEN1KMT2AUSP7POLB | |
| SCHEMBL13257003 | 0.82 | IGF1R (0.35) | HTR2CMEN1KMT2APIM1PIM3 | |
| SCHEMBL13257126 | 0.81 | HTR2C (0.38) | HTR2CMEN1KMT2AUSP7PIM1 | |
| Hydrochloric Acid SCHEMBL15310324 | 0.81 | HTR2C (0.36) | HTR2CMEN1KMT2APIM1PIM3 | |
| Hydrochloric Acid SCHEMBL3711181 | 0.80 | HTR2C (0.40) | HTR2CMEN1KMT2AUSP7PIM1 | |
| SCHEMBL1137793 | 0.80 | NPC1 (0.53) | METAP2MEN1KMT2ASLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387204-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| EP-2396330-B1 | FUSED PYRIMIDINES | BAYER IP GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8592591-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20130310362-A1 | FUSED PYRIMIDINES | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2013-11-21 | — | — | US | disclosed |
| EP-2396331-B1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER IP GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| CN-102317291-A | Fused pyrimidines | BAYER SCHERING PHARMA AG | 2012-01-11 | — | — | CN | disclosed |
| EP-2396330-A1 | FUSED PYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-21 | — | — | EP | disclosed |
| EP-2176259-B1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010091808-A1 | FUSED PYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010091824-A1 | FUSED PYRIMIDINES AS AKT INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-19 | — | — | WO | disclosed |
| EP-2176259-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| WO-2009021990-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | CCR1 3843/4885CCR8 3563/4885HTR2C 2543/4885 |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | CCR1 3843/4885CCR8 3563/4885HTR2C 2543/4885 |
| US-20130310362-A1 | FUSED PYRIMIDINES | PIK3CA, MTOR, PIK3CD | CCR1 3675/4885CCR8 3400/4885HTR2C 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.